Clinical Trial 21970

• Overview

  Study Title:

  A multicenter, open-label, first-in human (FIH), multiple expansion cohort, Phase 1/2 study to evaluate the safety and efficacy of DR-01 in adult subjects with large granular lymphocytic leukemia

  Summary:

  This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas.

  Objective:

  Primary Objectives: To evaluate the safety and tolerability of escalating doses of DR-01 in adult subjects with relapsed/refractory LGLL or cytotoxic lymphomas. To determine potential pharmacologically optimized dose/regimen(s) for DR-01 for the LGLL and cytotoxic lymphoma populations. Secondary Objectives: To estimate the overall response rate (ORR), complete response (CR) rate, and partial response (PR) rate based on disease-specific response criteria. To estimate the durability of response as measured by duration of response (DOR), best overall response (BOR), progression-free survival (PFS), overall survival (OS), and time to response. To characterize the PK profile of DR-01. To evaluate the immunogenicity of DR-01.

• Treatments

  Therapies:

  Non fucosylated human IgG1 antibody against CD94

  Medications:

  DR-01 ()

• Inclusion Criteria

  Inclusion Criteria:
  • 18 years of age or older.
  • Able to understand and comply with protocol-required study procedures and voluntarily sign a written informed consent document.
  • Sufficient key organ performance and coagulation.
  • Female patients of childbearing potential (postmenarcheal, has an intact uterus and at least one ovary, and is > Male patients must agree to use acceptable effective method(s) of contraception.
  • Patients with LGLL must also:
  • Must have discontinued at least one prior line of systemic therapy.
  • Additional immunophenotypic criteria must be met.
  • Disease-specific Inclusion Criteria (Cytotoxic Lymphomas):
  • Patients with cytotoxic lymphomas must also:
  • Must have failed at least two prior systemic regimens.
  • Availability of post-progression tissue sample or willingness to consent to a baseline biopsy.
  • Histologically confirmed diagnosis of a cytotoxic lymphoma by a hematopathologist (according to the WHO 2016 classification [Swerdlow 2016]).
  • For Part A only, evaluable disease is acceptable.
  • For Part B2 only: Patients must have radiographically measurable disease to be assessed by Lugano criteria. Subjects with primary cutaneous variants must have at least 1 measurable lesion that is evaluable using the Olsen criteria (Olsen 2021) or leukemic involvement that can be evaluated using a modified TPLL response criteria (Staber 2019). Patients with hepatosplenic disease or other variants that do not have measurable disease by Lugano criteria (Cheson 2014) may be eligible upon discussion with the Medical Monitor if they have identifiable leukemic involvement in BM or peripheral blood (meeting the CD8+ cytotoxic phenotype definition) that can be evaluated for response using a modified TPLL response criteria (Staber 2019), or skin involvement that can be evaluated using Olsen criteria (Olsen 2021).
  • Additional criteria may apply.

• Exclusion Criteria

  Exclusion Criteria: Disease-specific Exclusion Criteria; LGLL and ANKL:
  • A reactive LGL lymphocytosis to a viral infection or LGL associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The following exclusion criteria apply to all subjects:
  • Active systemic infection or severe localized infection requiring systemic antibiotics, antivirals or antifungals.
  • Active or suspected malignant central nervous system involvement.
  • Life-threatening, severe complications of malignancy (e.g., uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation).
  • Active known second malignancy.
  • Infection with human immunodeficiency virus (HIV) type 1 or 2 (HIV-1 or HIV-2).
  • Hepatitis B infection (hepatitis B virus surface antigen [HBsAg] positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid). Subjects with HCV with undetectable virus after treatment are eligible.
  • History of clinically significant cardiac disease or congestive heart failure greater than New York Heart Association (NYHA) Class II.
  • Use of systemic corticosteroids (e.g., less than 5 mg/day prednisone or equivalent for subjects with LGL leukemia (subjects on 20 mg prednisone or equivalent to treat LGL leukemia must be weaned within 28 days post C1D1 to 5 mg) and less than 0 mg/day prednisone or equivalent for subjects with cytotoxic lymphoma) within 15 days (except for prophylaxis for radiodiagnostic contrast reactions), or other non-biological immunosuppressive drugs within 15 days, prior to C1D1. Patients on stable prednisone less than or equal to 10 mg for documented rheumatologic/autoimmune conditions are exempted from this requirement.
  • Any condition requiring hormonal therapy (except for contraception, hormone replacement therapy and hormonal prophylaxis for a prior malignancy).
  • Any other medical or psychiatric condition, or laboratory abnormality that would increase the risk associated with study participation, in the opinion of the Investigator or Medical Monitor.
  • Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, peripheral neuropathy, or hematologic parameters meeting inclusion criteria).
  • Autologous HSCT within 40 days of C1D1, allogeneic HSCT within 90 days
  • Any immunosuppressive therapy for GVHD for subjects who are post allogeneic HSCT.
  • Major surgery within 28 days of C1D1 (requires more than local anesthesia or plexus blockade).
  • Other exclusions may apply.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.